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Abstract
While polygenic risk scores (PRS) have been shown to predict many diseases and risk factors, the potential of genomic
prediction in harm caused by alcohol use has not yet been extensively studied. Here, we built a novel polygenic risk
score of 1.1 million variants for alcohol consumption and studied its predictive capacity in 96,499 participants from the
FinnGen study and 39,695 participants from prospective cohorts with detailed baseline data and up to 25 years of
follow-up time. A 1 SD increase in the PRS was associated with 11.2 g (=0.93 drinks) higher weekly alcohol
consumption (CI= 9.85–12.58 g, p= 2.3 × 10–58). The PRS was associated with alcohol-related morbidity (4785
incident events) and the risk estimate between the highest and lowest quintiles of the PRS was 1.83 (95%
CI= 1.66–2.01, p= 1.6 × 10–36). When adjusted for self-reported alcohol consumption, education, marital status, and
gamma-glutamyl transferase blood levels in 28,639 participants with comprehensive baseline data from prospective
cohorts, the risk estimate between the highest and lowest quintiles of the PRS was 1.58 (CI= 1.26–1.99, p= 8.2 × 10–5).
The PRS was also associated with all-cause mortality with a risk estimate of 1.33 between the highest and lowest
quintiles (CI= 1.20–1.47, p= 4.5 × 10–8) in the adjusted model. In conclusion, the PRS for alcohol consumption
independently associates for both alcohol-related morbidity and all-cause mortality. Together, these ﬁndings underline
the importance of heritable factors in alcohol-related health burden while highlighting how measured genetic risk for
an important behavioral risk factor can be used to predict related health outcomes.
Introduction
Alcohol drinking is a major dose-dependent contributor
to morbidity and mortality. Globally, 3 million annual
deaths (5% of all deaths) result from alcohol consumption,
and is also linked to more than 200 disease and injury
outcomes1. As ethanol is a psychoactive substance with
addictive properties2, alcohol consumption can lead to the
development of alcohol use disorders (AUDs), globally
prevalent mental disorders of pathological addictive or
abusive drinking patterns, which are linked to worse
health outcomes, negative socioeconomic effects, and
increased mortality3. There is a strong connection
between the health burden and the level of alcohol con-
sumed4, and in total, alcohol has been estimated to be the
most damaging of all substances of abuse, in terms of
harm caused to self and others5.
Alcohol-related behaviors are also affected by genetic
factors and the estimated heritability of alcohol con-
sumption in twin studies has ranged between 35% and
65% (weighted average 37%)6 and its single nucleotide
polymorphism-based heritability has been estimated to be
10%7. Recent large-scale genome-wide association studies
(GWAS) have identiﬁed multiple loci associated with
alcohol consumption, underlining the importance of large
study populations for unraveling the genetic architecture
underlying alcohol-related traits7,8. Similarly, GWAS of
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alcohol dependence, AUD, and the Alcohol Use Disorders
Identiﬁcation Test (AUDIT) scores have shown the traits
to be genetically distinct but positively correlated9–11.
Polygenic risk scores (PRSs) derived from GWAS
summary statistics have showcased improved perfor-
mance in disease prediction12. PRSs for known risk factors
have also been shown to associate with the related dis-
ease13, and recently associations between multiple risk
factor PRSs and related traits were conﬁrmed and
reported14,15. However, the link between PRSs for beha-
vioral traits and associated health outcomes remains
poorly understood.
The assessment of potential health risks related to
alcohol has so far relied on traditional risk factors,
including family history, without explicit measurement of
genetic risk. Here we developed a highly polygenic risk
score for alcohol consumption and studied whether
alcohol-related polygenic burden predicts alcohol-use
disorders and other alcohol-related morbidity and mor-
tality in Finnish biobank cohorts (n= 96,499) linked to
electronic health records. Furthermore, we studied whe-
ther the PRS for alcohol consumption predicts alcohol-
related outcomes beyond self-reported alcohol con-
sumption and other related risk factors, thus providing
more objective information independent of individual
reporting bias or temporal ﬂuctuations.
Methods
Study sample and deﬁnition of alcohol-related morbidity
The data are comprised of 96,499 Finnish individuals
from FinnGen Data Freeze 2 (https://www.ﬁnngen.ﬁ/),
which includes prospective epidemiological and disease-
based cohorts as well as hospital biobank samples (Con-
tributors S1, Table S1). The data were linked by the
unique national personal identiﬁcation numbers to
national hospital discharge, death, and medication reim-
bursement registries. Additional details and information
on the genotyping and imputation are provided in the
online-only Supplementary Information.
Alcohol-related baseline measures were available for a
subset of the FinnGen dataset consisting of national
population survey cohorts: FINRISK, collected in 1992,
1997, 2002, 2007, and 2012 and Health 2000, collected in
2000. The baseline data included self-reported informa-
tion assessed by questionnaires, anthropometric mea-
sures, and blood samples. More detailed descriptions of
the FINRISK and Health 2000 studies have been pub-
lished previously16,17.
Additionally, three Finnish twin cohorts, FinnTwin12,
NAG-FIN, and Old Twin, were pooled and analyzed as
one dataset. For these datasets, cohort baseline data were
available, but the cohorts were not linked to electronical
health records. For details regarding the twin datasets, see
the online descriptions (https://wiki.helsinki.ﬁ/display/
twineng/Twinstudy)18,19.
Using nationwide registries for deaths (1969–2016),
hospital discharges (1969–2016), outpatient specialist
appointments (1998–2016), and drug purchases
(1995–2016), we combined 21 somatic and psychiatric
alcohol-related diagnoses into a composite disease end-
point, harmonizing the International Classiﬁcation of
Diseases (ICD) revisions 8, 9, and 10, and ATC-codes
(Table S2). These registries spanning decades were elec-
tronically linked to the cohort baseline data using the
unique national personal identiﬁcation numbers assigned
to all Finnish citizens and residents. The ﬁnal alcohol-
related morbidity endpoint was deﬁned as the ﬁrst single
event coded as any of the conditions in the composite
endpoint.
Genotyping and imputation
FinnGen, FINRISK, Health 2000, and Finnish Twin
Cohort samples were genotyped with Illumina and Affy-
metrix genomewide SNP arrays. Individuals with non-
European ancestry or uncertain sex were excluded.
Within each cohort, every genotyping batch was ﬁrst
imputed separately and then merged together for asso-
ciation analyses. The details about the genotype calling,
quality controls, and imputation are provided in the
Supplementary material (Methods S1).
Polygenic risk scores
Summary statistics from the largest existing GWAS
meta-analysis on alcohol consumption (8) were used for
constructing the PRS. To avoid overﬁtting, a separate ad
hoc meta-analysis was performed by GSCAN (Con-
tributors S2), excluding all Finnish and 23andMe samples
(n= 527,282 after exclusions). LDpred-method20 was
used to account for linkage disequilibrium (LD) among
loci with whole-genome sequencing data on 2690 Finns
serving as the external LD reference panel. We compared
the PRSs generated with LDpred-parameters and their
predictive ability in FINRISK (Fig S1). Any threshold
above 0.003 worked practically similarly, and for simpli-
city we chose to use the LDpred-inf PRS in all the ana-
lyses. The ﬁnal scores were generated with PLINK2
(ref. 21) by calculating the weighted sum of risk allele
dosages for each variant. The number of variants in the
ﬁnal scores was 1.1 million (1,134,960 in FinnGen,
1,143,220 in FINRISK and Health 2000, and 1,143,138 in
the Twin Cohort).
Statistical analysis
The Cox proportional hazard model was used to esti-
mate survival curves, hazard ratios (HRs), and 95% con-
ﬁdence interval (95% CI) in the survival analyses where
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age was used as the time scale. R’s cox.zph function was
used to test whether the proportional assumption criteria
applied in our models. Linear regression in FINRISK and
Health 2000 and linear mixed model in the Twin Cohort
was used for estimating the relationship between the PRS
and alcohol consumption. Logistic regression in the
FINRISK and Health 2000 cohorts and linear mixed
model in the Twin Cohort was used to estimate the
relationship between alcohol abstinence and the PRS.
All the cohorts (FinnGen, FINRISK, Health 2000, and
the Twin Cohort) were analyzed independently as single
datasets where age, sex, genotyping array, and the ﬁrst ten
principal components of ancestry were used as core
covariates. Additionally, body mass was used as a cov-
ariate in the model estimating the PRS–alcohol con-
sumption relationship. Self-reported weekly average
alcohol consumption from the past year (when unavail-
able, the past week’s consumption) was used as the esti-
mate for alcohol consumption. In the fully adjusted
survival model analyses, log(x+ 1) -transformed alcohol
consumption-estimate, current smoking status, binary
higher education status, binary marital/cohabitation sta-
tus, and gamma-glutamyl transferase (GGT) blood levels
at baseline served as covariates. The GGT levels were
measured following uniform recommendations of the
European Committee for Clinical Laboratory Standards
(ECCLS)22 enabling comparability between the cohorts.
In the survival analyses, all prevalent cases (in FINRISK
and Health 2000) and individuals with covariate miss-
ingness were excluded. The PRS was normalized and
included as a continuous variable in the models. In the
survival analysis, the highest and lowest genetic risk for
alcohol consumption were compared using PRS quintiles.
In analyses using baseline consumption data, the ana-
lyses were performed separately in the Health 2000,
FINRISK Study, and Twin Cohorts and then meta-
analyzed using ﬁxed effects model.
In risk prediction, FINRISK cohorts with at least 10
years of follow-up (from 1992 to 2002) were used to train
the model, and the predictive performance was tested in
the Health 2000 cohort. The maximal follow-up window
was restricted to 10 years. The change in the predictive
performance was assessed by comparing models with and
without the PRS using the correlated C-index approach23
along with calculating the continuous reclassiﬁcation
improvement (NRI)24 and integrated discrimination
improvement (IDI)25. The Hosmer–Lemeshow goodness-
of-ﬁt test was used to test model calibration.
Ethical approval
The study was conducted in accordance with the princi-
ples of the Helsinki declaration. Written informed consent
was obtained from all the study participants. For the Finnish
Institute of Health and Welfare (THL)-driven FinnGen
preparatory project and FinnGen project, all patients and
control subjects had provided informed consent for biobank
research, based on the Finnish Biobank Act. Alternatively,
FINRISK and Health 2000 cohorts were based on study
speciﬁc consents and later transferred to the THL Biobank
after approval by Valvira, the National Supervisory
Authority for Welfare and Health. Recruitment protocols
followed the biobank protocols approved by Valvira. The
Biobank Access Decisions for FinnGen samples and data
utilized in FinnGen Data Freeze 2 include: Auria Biobank
AB17-5154, THL Biobank BB2017_55, BB2017_111,
BB2018_19, BB_2018_34, Finnish Red Cross Blood Service
Biobank 7.12.2017, Helsinki Biobank HUS/359/2017 and
Northern Finland Biobank Borealis BB_2017_1013. The
Ethical Review Board of the Hospital District of Helsinki
and Uusimaa approved the FinnGen study protocol Nr
HUS/990/2017. The FinnGen preparatory project as well as
the FinnGen project was approved by THL, approval
numbers THL/2031/6.02.00/2017, amendments THL/341/
6.02.00/2018, THL/2222/6.02.00/2018, THL/1101/5.05.00/
2017, VRK43431/2017-3, KELA 131/522/2018, and Statis-
tics Finland TK-53-1041-17. The Twin Cohort studies
were approved by the Coordinating Ethical Committee of
the Helsinki and Uusimaa Hospital District, reference
numbers 246/13/03/00/15, 113/E3/2001, and HUS/1169/
2016. The transfer of the FINRISK and Health
2000 sample collections to the THL biobank has been
approved by the Coordinating Ethics Committee of Hel-
sinki University Hospital on 10 October 2014 and by the
Ministry of Social Affairs and Health on 9 March 2015.
This study was conducted under the THL biobank per-
mission BB2017_64 (FINRISK and Health 2000). No
additional ethical approval was needed for meta-analyzing
the results. All DNA samples and data in this study were
pseudonymized.
Results
Cohorts
Our primary dataset (FinnGen) is comprised of 96,499
unrelated individuals (54,262 women) with a total of
55,484,114 person-years of registry-based follow-up and
4785 ﬁrst-observed alcohol-related major health events.
Alcohol consumption estimates were available for a total
of 39,695 individuals from the prospective cohorts (FIN-
RISK, Health 2000, and Twin Cohort, Fig. S2). Two
cohorts, FINRISK and Health 2000, have full registry data
and information on self-reported alcohol consumption
and related baseline data, and consist of 28,639 individuals
(94.5% of the participants after excluding 964 prevalent
alcohol-related morbidity cases), with 424,053 person-
years of registry-based follow-up and 988 ﬁrst ever
alcohol-related events (Table 1). The interview-based
DSM-IV AUD-status was available in a subset of the Twin
cohort for 713 cases and 1460 controls.
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Alcohol consumption
In a meta-analysis of the three cohorts with alcohol
consumption estimates available (n= 39,695), the PRS for
alcohol consumption was strongly associated with self-
reported alcohol consumption. A 1 SD increase in the PRS
was associated with an 11.2 g (=0.93 drinks á 12 g)
increase in weekly pure alcohol intake (beta= 11.2
[9.85–12.6 g], p= 2.3 × 10–58) (Fig. 1, cohort-speciﬁc ﬁg-
ures: Fig. S3). Adding the PRS to the model improved r2
by ~0.6 percentage points (from 9.17% to 9.80%). In
addition, the PRS was negatively associated with alcohol
abstinence (reported alcohol consumption 0). In FINRISK
and Health2000, a 1 SD increase in the PRS for alcohol
consumption was associated with a 13.7% reduced like-
lihood of being a nondrinker (OR= 0.863 [0.833–0.895],
p= 6.1 × 10–16) while this was not the case in the Twin
Cohort where there were only 30 nondrinkers (OR=
0.999 [0.998–1.00] p= 0.31).
Alcohol-related morbidity
The PRS for alcohol consumption was strongly asso-
ciated with increased risk for lifelong major alcohol-
related events derived from electronic health-records in
the FinnGen dataset (n= 96,499, cases= 4785) (Fig. 2).
The difference in the risk for alcohol-related morbidity
events between the lowest and highest risk quintiles in the
PRS was 83% (HR= 1.83 [1.66–2.01], p= 1.6 × 10–36) and
Table 1 Population characteristics of FinnGen, FINRISK, Health 2000, and Twin Cohort datasets.
FinnGen FINRISK Health 2000 Twin Cohort
N 96,499 (54,262 women) 23,824 (12,513) 5945 (3260) 9926 (5036)
N (incident events) 4785 817 171 NA
Age (years) 57.5 (end of follow-up) 48.6 (baseline) 54.0 (baseline) 49.3 (baseline)
Alcohol drinking (g/week) NA 76.5 73.9 84.8
Non-drinkers NA 2874 (12%) 1298 (22%) 30 (0.3%)
Current smokers NA 5929 (25%) 1538 (26%) 3478 (35%)
Higher education NA 8612 (36%) 1721 (28%) 1192 (12%)
Marriage or co-habitation NA 17,468 (73%) 4151 (68%) 6661 (67%)
GGT (U/I) NA 33.8 36.6 NA
Fig. 1 Alcohol drinking (g/week) for the deciles of the alcohol
consumption polygenic risk score. The association is shown for
males (n= 18,887) and females (n= 20,808) with 95% conﬁdence
interval error bars (n= 39,695). Fig. 2 Cumulative hazard risk comparison of alcohol
consumption polygenic risk score quintiles. The FinnGen dataset
was divided into three groups consisting of the lowest quintile, three
middle quintiles, and the highest quintile of the alcohol consumption
PRS. The cumulative disease rate of alcohol-related morbidity is
displayed as a function of age (n= 96,499).
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a 1 SD increase in the PRS was associated with a 26%
increase in risk (HR= 1.26 [1.23–1.30], p= 5.7 × 10–56).
The association was similar in both males (HR= 1.26
[1.22–1.31], p= 1.3 × 10–38) and females (HR= 1.27
[1.20–1.33], p= 4.8 × 10–19).
In the cohorts where alcohol consumption estimates
and other related baseline data were available at the
cohort entry time, the PRS was associated with an
increased risk of incident major alcohol-related events
and the association was maintained also in the fully
adjusted model (n= 28,639, cases= 911). In a meta-
analysis of the two cohorts, 1 PRS SD was associated with
a 26% increased risk of incident alcohol-related events
when the consumption-estimate was not in the model
(HR= 1.26 [1.18–1.34], p= 1.1 × 0–12) and with a 15%
increase when alcohol consumption was in the model
(HR= 1.15 [1.08–1.22], p= 2.1 × 10–5). In a fully adjusted
model, including marital status, education, smoking sta-
tus, and GGT, the estimate was unchanged (HR= 1.15
[1.08–1.22], p= 2.0 × 10–5) (Table 2). The risk estimate
between the highest and lowest quintiles of the PRS in
the fully adjusted model was 1.58 (HR= 1.58 [1.26–1.99],
p= 8.2 × 10–5).
Mortality
We observed a similar increase in the risk of alcohol-
related and all-cause mortality. In FinnGen with 7249
deaths, 1 SD increase in the PRS for alcohol consumption
was associated with 8% increase in the risk of death (HR
= 1.08 [1.06–1.11], p= 2.0 × 10–11). The risk estimate
between the highest and lowest 20% in the PRS was 1.27
(HR= 1.27 [1.18–1.37], p= 2.1 × 10–10). In our pro-
spective cohorts, with cause-of-death information avail-
able, 4125 deaths were recorded. For all-cause mortality,
there was 11% increase in the risk of death per 1 PRS SD
in the basic model (HR= 1.11 [1.07–1.14], p= 3.2 ×
10–10) and 9% in the fully adjusted model (HR= 1.09
[1.06–1.12], p= 1.1 × 10–7). The risk difference between
the highest and lowest quintiles of the PRS was 33%
(HR= 1.33 [1.2–1.47], p= 4.5e−08) in the fully
adjusted model.
Of the 4125 deaths, 335 were known to be alcohol-
related. Without alcohol consumption in the model, the
increase in alcohol-related mortality was 26% per 1 PRS
SD (HR= 1.26 [1.13–1.4], p= 3.7 × 10–5). When alcohol
consumption was included in the model, the increase was
13% (HR= 1.13 [1.01–1.26], p= 0.027) and in a model
with all co-variates, 11% (HR= 1.11 [0.996–1.24], p=
0.058) (Table 2). Similarly, the PRS was associated with a
higher risk of death from other than alcohol-related
causes (n= 3790) when fully adjusted for all covariates
(HR= 1.08 [1.05–1.12], p= 1.4 × 10–6).
DSM-IV alcohol-use disorder
The PRS was also associated with an interview-based
DSM-IV AUD diagnosis in the Nicotine Addiction
Genetics Family cohort (440 cases, 1140 controls) and a
subset of FinnTwin16 cohort (273 cases, 320 controls). A
meta-analysis of the two cohorts (713 cases) resulted in a
combined 20% increase in the prevalence of AUD per 1
PRS SD (OR= 1.20 [1.11–1.31], p= 2.29 × 10–5) in the
unadjusted model. Adjusting for marital status, education,
and smoking explained part of the effect (OR= 1.14
[1.02–1.28], p= 0.023) and further adjusting with max-
imal amount of drinks taken explained most of the effect
(OR= 1.06 [0.94–1.19], p= 0.35).
Prediction
The predictive performance of the PRS was evaluated in
the Health 2000 cohort (5732 complete cases, 110 events)
with a follow-up-window of 10 years based on the Cox
model trained in the FINRISK cohort (18,427 complete
cases with ≥ 10 years of follow-up, 628 events). In a model
not including the alcohol consumption estimate, adding
Table 2 Cohort speciﬁc and meta-analyzed associations between the alcohol consumption PRS and alcohol-related (a)
morbidity and (b) mortality.
FINRISK Health 2000 Meta-analysis
(a) Alcohol-related morbidity Cases= 817 Cases= 171 Cases= 988
Basic model with age and sex HR= 1.25 [1.16–1.34], p= 5.9 × 10–10 HR= 1.32 [1.13–1.53], p= 0.00036 HR= 1.26 [1.18–1.34], p= 1.1 × 10–12
Model with alcohol consumption HR= 1.13 [1.06–1.21], p= 0.00053 HR= 1.23 [1.06–1.43], p= 0.0081 HR= 1.15 [1.08–1.22], p= 2.1 × 10–5
Fully adjusted model HR= 1.14 [1.06–1.22], p= 0.00027 HR= 1.20 [1.03–1.4], p= 0.022 HR= 1.15 [1.08–1.22], p= 2.0 × 10–5
(b) Alcohol-related mortality Deaths= 264 Deaths= 71 Deaths= 335
Basic model with age and sex HR= 1.21 [1.07–1.37], p= 0.0022 HR= 1.41 [1.11-1.8], p= 0.0045 HR= 1.25 [1.12-1.4], p= 5.9 × 10–5
Model with alcohol consumption HR= 1.08 [0.952–1.22], p= 0.24 HR= 1.34 [1.05–1.71], p= 0.017 HR= 1.13 [1.01–1.26], p= 0.033
Fully adjusted model HR= 1.08 [0.957–1.23], p= 0.21 HR= 1.22 [0.965–1.55], p= 0.096 HR= 1.11 [0.996–1.24], p= 0.058
In the fully adjusted model, age, sex, alcohol consumption, smoking, education, marital status, and GGT (U/I) were used as non-genetic covariates
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the PRS to the model increased the C-index by 0.020,
from 0.69 to 0.71 (p= 0.017). Both IDI (0.00242
[0.00102–0.00383], p= 7.3 × 10–4) and NRI (0.335
[0.146–0.523], p= 5.1 × 10–3) shifts were positive and
statistically signiﬁcant. When the log-transformed alcohol
consumption estimate was included, a minimal improve-
ment of prediction was observed (C-index= 0.0022 from
0.812 to 0.814, p-value= 0.30; NRI= 0.308 [0.119–0.497],
p= 0.0014 and IDI= 0.00173 [0.000726–0.00305], p=
0.017). Similarly, a minimal gain was observed when
adding PRS to a model with all available covariates
including also marital status, education status, smoking
status, and GGT (C-index= 0.00183 from 0.847 to 0.849,
p= 0.44; NRI= 0.235 [0.0461–0.423], p= 0.015; IDI=
0.00331 [0.0000254–0.00659], p= 0.048).
Discussion
We developed a highly polygenic risk score for alcohol
consumption by obtaining weights from a recently pub-
lished large-scale discovery sample and showed that the
PRS was strongly associated with alcohol consumption in
independent biobank cohort samples. An increased
polygenic burden for alcohol consumption was associated
with higher incidence of major alcohol-induced health
events. The associations remained signiﬁcant when we
accounted for self-reported alcohol consumption and
other relevant covariates; in a fully adjusted model, the
relative risk-estimate between the highest and lowest
quintiles of the PRS was 1.6. Furthermore, the PRS was
also associated with both alcohol-related, non-alcohol
related, and all-cause mortality.
Our PRS shows the utility of genetic information for
prediction of alcohol-related harm. The PRS, developed
from a genetic analysis of cross-sectional self-reported
alcohol consumption, was associated with future risk of
major alcohol-related health events. While a large number
of PRSs have already been established for various traits
and diseases12, the development of PRSs for behavioral
traits, such as substance use, has until now been lim-
ited26–29 and the studies have not assessed their impact on
future major health events.
Our results show that using a large sample size with
long follow-up, we were able to build a PRS of alcohol
consumption that is associated not only with alcohol
consumption in independent samples, but also with future
incident alcohol-related health events. In line with the
knowledge that alcohol consumption is a major con-
tributor to the worldwide burden of death, especially
among working-age adults1, we found the PRS to be
associated also with all-cause mortality, further high-
lighting the importance of alcohol drinking as a cause of
premature death.
Our score provides a genetic basis for potentially
identifying a subset of high-risk individuals even early on
in life, with potential for more targeted prevention of
AUDs and other alcohol-related morbidity. Prevention is
a cost-effective and efﬁcient strategy to reduce alcohol-
related harms30 and it is labeled one of the United Nations
main health-related worldwide strategies of sustainable
development (https://sustainabledevelopment.un.org/
sdg3). A higher genetic predisposition for alcohol-
related harms was detected both in the presence and
absence of alcohol consumption data, as our PRS pre-
dicted alcohol-related harms beyond self-reported alcohol
consumption. Health services are encouraged to support
initiatives for screening and brief interventions for
harmful drinking31 as an effective strategy for tackling
alcohol-related harm32. Thus, genetic information could
potentially be used to improve the arsenal of possible
strategies to detect high-risk individuals for targets of
brief interventions. The fact that individuals in the highest
PRS quintile showed an elevated risk for alcohol-related
health events even in fully adjusted models could justify
the use of genetic information even in clinical settings
where a detailed history of alcohol consumption esti-
mates, AUDIT-scores, or similar information are attain-
able. Communicating the information of higher risk for
alcohol-related harm to patients could serve as a moti-
vator for reducing drinking or committing to abstinence.
However, the true effects of informing patients about their
alcohol-related genomic risk warrants further research.
Self-reported alcohol consumption is known to be
biased and problematic in terms of reliability and validity
for predicting alcohol-related risks33,34. Also, GGT is
known to be less-than-ideal biochemical measure of
drinking35. Some inaccuracy derives from true measure-
ment error, but another source is the lifelong temporal
ﬂuctuation of alcohol-drinking patterns not captured by a
measure at one single timepoint. Our PRS was associated
with alcohol-related harms even when adjusting for self-
reported alcohol consumption estimate. One potential
reason for this is that the PRS contains information from
the latent genetic predisposition for alcohol consumption,
thus overriding both the true measurement error and
temporal ﬂuctuations in alcohol drinking volume.
Furthermore, it has been hypothesized that alcohol
consumption-based genetic discovery might inform more
about low-level drinking than about problematic drinking
and AUDs36. However, we built a PRS for alcohol con-
sumption and successfully used it to predict alcohol-
related harms. Due to the robustness of a self-reported
single timepoint alcohol consumption estimate and the
fact that different alcohol-related traits are to some degree
genetically distinct9–11, it is expected that a PRS devel-
oped directly for alcohol-related morbidity will outper-
form our PRS in predicting alcohol-related health burden.
Supporting this assumption, the general pattern is that
PRSs are more strongly associated with their respective
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diseases than with related phenotypes.14,15. Unfortunately,
no high-quality summary statistics for alcohol-related
harms including both somatic and psychiatric outcomes
yet exist; the performed GWAS have only covered AUD
and alcohol dependence10,11 and been smaller in size than
our discovery sample of choice, thus making future efforts
for large-scale GWAS discovery based on alcohol-related
harms more than necessary.
Our PRS was derived using European ancestry discovery
samples and tested in the Finnish population. Its applic-
ability in other populations therefore needs further eva-
luation as the alcohol-related genetic mechanisms may
vary between populations. However, it has to be noted
that the PRS derived from a non-Finnish sample per-
formed well in the Finnish dataset, even though Finns are
somewhat genetically different from the rest of the
Europeans37.
Our design allowed us to study outcomes prospectively.
Our registry-based follow-up captures alcohol-related
outpatient and inpatient visits, withdrawal treatment
prescription for alcoholism, and deaths, thus covering
major alcohol-related health events over several decades.
Nonetheless, some of the milder cases of alcohol-related
health problems could have gone undetected.
In conclusion, a PRS for alcohol consumption was
associated with elevated risk for incident alcohol-related
health events and all-cause mortality. These ﬁndings
underline the importance of heritable factors driving
alcohol-related behavior. A successful attempt to predict
alcohol-related health outcomes with a PRS shows pro-
mise in possible future utilization of genetic information
in risk estimation and prediction of alcohol-related harms.
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